Patents by Inventor Steven W. Andrews

Steven W. Andrews has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
    Patent number: 7060844
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Grant
    Filed: April 1, 2003
    Date of Patent: June 13, 2006
    Assignee: Allergan, Inc.
    Inventors: Steven W. Andrews, Xialing Guo, Zhen Zhu, Clarence E. Hull, III, Julie A. Wurster, Shimiao Wang, Edward H. Wang, Thomas Malone
  • 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors
    Patent number: 7015220
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Grant
    Filed: February 20, 2004
    Date of Patent: March 21, 2006
    Assignee: Allergan, Inc.
    Inventors: Steven W. Andrews, Julie A. Wurster, Edward H. Wang, Thomas Malone
  • 3-(heteroarylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors
    Patent number: 7005444
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Grant
    Filed: September 26, 2002
    Date of Patent: February 28, 2006
    Assignee: Allergan, Inc.
    Inventors: Steven W. Andrews, Julie A. Wurster
  • 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors
    Publication number: 20040198720
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Application
    Filed: February 20, 2004
    Publication date: October 7, 2004
    Inventors: Steven W. Andrews, Julie A. Wurster, Edward H. Wang, Thomas Malone
  • Kinase inhibitors for the treatment of disease
    Publication number: 20040198802
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Application
    Filed: April 20, 2004
    Publication date: October 7, 2004
    Applicant: Allergan, Inc.
    Inventors: Steven W. Andrews, Michael E. Garst, Xialing Guo, Jonathan J. Hebert, Thomas Malone, Julie A. Wurster, Clarence Eugene Hull
  • 3-(Arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
    Patent number: 6765012
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Grant
    Filed: September 27, 2002
    Date of Patent: July 20, 2004
    Assignee: Allergan, Inc.
    Inventors: Steven W. Andrews, Julie A. Wurster, Edward H. Wang, Thomas Malone
  • Kinase inhibitors for the treatment of disease
    Patent number: 6747025
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell poliferation.
    Type: Grant
    Filed: March 13, 2003
    Date of Patent: June 8, 2004
    Assignee: Allergan, Inc.
    Inventors: Steven W. Andrews, Michael E. Garst, Xialing Guo, Jonathan J. Hebert, Thomas Malone, Julie A. Wurster, Clarence Eugene Hull, III
  • KINASE INHIBITORS FOR THE TREATMENT OF DISEASE
    Publication number: 20040102509
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Application
    Filed: March 13, 2003
    Publication date: May 27, 2004
    Applicant: Allergan, Inc.
    Inventors: Steven W. Andrews, Michael E. Garst, Xialing Guo, Jonathan J. Hebert, Thomas Malone, Julie A. Wurster, Clarence Eugene Hull
  • Kinase inhibitors for the treatment of disease
    Patent number: 6699863
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Grant
    Filed: November 27, 2002
    Date of Patent: March 2, 2004
    Assignee: Allergan, Inc.
    Inventors: Steven W. Andrews, Jonathan J. Hebert
  • (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
    Publication number: 20040019098
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Application
    Filed: April 1, 2003
    Publication date: January 29, 2004
    Applicant: Allergan, Inc.
    Inventors: Steven W. Andrews, Xialing Guo, Zhen Zhu, Clarence E. Hull, Julie A. Wurster, Shimiao Wang, Edward H. Wang, Thomas Malone
  • 3-(Arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors
    Publication number: 20030225152
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Application
    Filed: September 27, 2002
    Publication date: December 4, 2003
    Inventors: Steven W. Andrews, Julie A. Wurster, Clarence E. Hull,
  • 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors
    Publication number: 20030199478
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Application
    Filed: September 27, 2002
    Publication date: October 23, 2003
    Inventors: Steven W. Andrews, Julie A. Wurster, Edward H. Wang, Thomas Malone
  • 3-(Heteroarylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors
    Publication number: 20030130328
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Application
    Filed: September 26, 2002
    Publication date: July 10, 2003
    Inventors: Steven W. Andrews, Julie A. Wurster
  • Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
    Publication number: 20030114528
    Abstract: The present invention provides cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compounds, which may be substituted in the 1-position with amino, amido, ether or ester groups, e.g., a 1-OH cyclopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) compound. The cyclopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) compounds of the present invention are potent ocular hypotensives, and are particularly suitable for the management of glaucoma. Moreover, the cyclopentane heptanoic, 2-(cycloalkyl or arylalkyl) compounds of this invention are smooth muscle relaxants with broad application in systemic hypertensive and pulmonary diseases; smooth muscle relaxants with application in gastrointestinal disease, reproduction, fertility, incontinence, shock, etc.
    Type: Application
    Filed: October 28, 2002
    Publication date: June 19, 2003
    Inventors: David F. Woodward, Steven W. Andrews, Robert M. Burk, Michael E. Garst
  • 3-(heteroarylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
    Patent number: 6559173
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Grant
    Filed: September 26, 2002
    Date of Patent: May 6, 2003
    Assignee: Allergan, Inc.
    Inventors: Steven W. Andrews, Julie A. Wurster
  • (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
    Patent number: 6541504
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Grant
    Filed: April 3, 2002
    Date of Patent: April 1, 2003
    Assignee: Allergan Sales, LLC
    Inventors: Steven W. Andrews, Julie A. Wurster, Clarence E. Hull, III, Edward H. Wang, Thomas Malone, Xialing Guo, Zhen Zhu
  • Non-acidic cyclopentane heptanoic acid,2-cycloalkyl or arylalkyl derivatives as therapeutic agents
    Patent number: 6403649
    Abstract: The present invention provides cydopentane heptanoic acid, 2-cycloalkyl or arylalkyl compounds, which may be substituted in the 1-position with amino, amido, ether or ester groups, e.g., a 1-OH cydopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) compound. The cydopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) compounds of the present invention are potent ocular hypotensives, and are particularly suitable for the management of glaucoma. Moreover, the cydopentane heptanoic, 2-(cycloalkyl or arylalkyl) compounds of this invention are smooth muscle relaxants with broad application in systemic hypertensive and pulmonary diseases; smooth muscle relaxants with application in gastrointestinal disease, reproduction, fertility, incontinence, shock, etc.
    Type: Grant
    Filed: March 6, 2000
    Date of Patent: June 11, 2002
    Assignee: Allergan Sales, Inc.
    Inventors: David F. Woodward, Steven W. Andrews, Robert M. Burk, Michael E. Garst
  • Ocular hypotensive lipids
    Patent number: 6395787
    Abstract: Compounds of Formula 1, where the symbols are as defined in the specification, are useful as ocular hypotensive agents but do not exert their activity through the FP prostaglandin receptor. In particular the compound PGF2&agr; 1-ethanolamide, having the formula was discovered to be present in mammalian tissue as a naturally occurring substance, was synthesized in a substantially pure form and was found to be effective for lowering intraocular pressure in the mammalian eye, but not acting through the FP receptor through which many ocular hypotensive prostaglandins act.
    Type: Grant
    Filed: February 8, 2000
    Date of Patent: May 28, 2002
    Assignee: Allergan Sales, Inc.
    Inventors: David F. Woodward, Helen H. Usansky, Steven W. Andrews, Robert M. Burk, June Chen, Achim H-P. Krauss, Cherukury Madhu
  • Cyclopentane (ene) oic acid, 2-alkenyl derivatives as therapeutic agents
    Patent number: 6258844
    Abstract: The invention relates to the use of omega chain modified prostaglandins as ocular hypotensive. The derivatives used in accordance with the invention are encompassed by the following structure formula I: wherein the hatched segments represent &agr; bonds; the wavy segment represents an &agr; or &bgr; bond; dashed lines represent a double bond or a single bond; X is selected from the group consisting of —OR and N(R2); Y is=O or represents 2 hydrogen radicals, provided that Y represents 2 hydrogen radicals when X is OH; R is hydrogen or a lower alkyl radical having up to six carbon atoms; R1 is=O or hydroxy; m is 0, 2, 4 or 6, provided that m is not 4 when the wavy segment represents a &bgr; bond; n is 0, 2, 4 or 6; x and y are 0 or 1, provided that x is 1 when y is 0 and y is 1 when x is 0; or 9, 11 and/or 15 ester derivatives of said compound of formula I, e.g. a C1 to C6 alkyl ester derivative; or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: November 24, 1998
    Date of Patent: July 10, 2001
    Assignee: Allergan Sales, Inc.
    Inventors: Michael E. Garst, Michael B. Roof, Ming F. Chan, David F. Woodward, Robert M. Burk, Todd S. Gac, Steven W. Andrews
  • Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
    Patent number: 5688819
    Abstract: The present invention provides cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compounds, which may be substituted in the 1-position with amino, amido, ether or ester groups, e.g., a 1-OH cyclopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) compound. The cyclopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) compounds of the present invention are potent ocular hypotensives, and are particularly suitable for the management of glaucoma. Moreover, the cyclopentane heptanoic, 2-(cycloalkyl or arylalkyl) compounds of this invention are smooth muscle relaxants with broad application in systemic hypertensive and pulmonary diseases; smooth muscle relaxants with application in gastrointestinal disease, reproduction, fertility, incontinence, shock, etc.
    Type: Grant
    Filed: February 22, 1996
    Date of Patent: November 18, 1997
    Assignee: Allergan
    Inventors: David F. Woodward, Steven W. Andrews, Robert M. Burk, Michael E. Garst